The project planned by ExploRNA Therapeutics – spin-off company of the University of Warsaw – involves the development of an improved mRNA with modified end of the 5' (cap), encoding neoantigens. This modified mRNA can be used to create experimental, therapeutic anticancer vaccines. The project provides for a verification of the safety of the developed immunotherapy and the ability to induction antigen-specific T lymphocytes in the group of patients with melanoma. The project will be based on the results of earlier works of the ExploRNA staff, carried out at the University of Warsaw, of which the Company is the exclusive licensee. The solution will be a product innovation in the world. As a result of the project, a unique process innovation in the form of a technology of cheap and highly efficient therapeutic production of mRNA on a large scale will also be created, which today is one of the most important barriers to the development and dissemination of mRNA-based therapies. The licensor of the solutions resulting from the Project will be an entity in the sector “BigPharma” (or a specialised biotechnology company) focusing on the development of oncological immunotherapy. This entity will be responsible for carrying out, in cooperation with the Applicant, further phases of clinical trials and marketing authorisations in accordance with Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014)